Hepatocellular carcinoma: the tumor and the liver

1. A. Continue ultrasound and AFP every 6 months (Why this does not fit)

   The obscured liver makes repeat ultrasound unreliable despite continued cirrhotic risk. [1]

   Reasoning steps for option A

   1. Does sustained HCV clearance erase this patient's established risk?

      No. Prior biopsy-proven cirrhosis remains a surveillance indication; the inadequate ultrasound determines how to perform it.

   2. How do the findings support or oppose this plan: Continue ultrasound and AFP every 6 months?

      The obscured liver makes repeat ultrasound unreliable despite continued cirrhotic risk. [1]

2. B. Use an MRI-based surveillance strategy with AFP (Best answer)

   Cirrhosis-associated risk persists after cure; an MRI-based alternative is reasonable when ultrasound remains severely limited. [1]

   Reasoning steps for option B

   1. Does sustained HCV clearance erase this patient's established risk?

      No. Prior biopsy-proven cirrhosis remains a surveillance indication; the inadequate ultrasound determines how to perform it.

   2. How do the findings support or oppose this plan: Use an MRI-based surveillance strategy with AFP?

      Cirrhosis-associated risk persists after cure; an MRI-based alternative is reasonable when ultrasound remains severely limited. [1]

3. C. Stop HCC surveillance after sustained viral clearance (Why this does not fit)

   Viral cure reduces HCC risk but does not eliminate the surveillance indication created by prior established cirrhosis. Residual cancer risk, not a claim that fibrosis can never regress, justifies continued surveillance. [1]

   Reasoning steps for option C

   1. Does sustained HCV clearance erase this patient's established risk?

      No. Prior biopsy-proven cirrhosis remains a surveillance indication; the inadequate ultrasound determines how to perform it.

   2. How do the findings support or oppose this plan: Stop HCC surveillance after sustained viral clearance?

      Viral cure reduces HCC risk but does not eliminate the surveillance indication created by prior established cirrhosis. Residual cancer risk, not a claim that fibrosis can never regress, justifies continued surveillance. [1]

4. D. Use AFP surveillance without liver imaging (Why this does not fit)

   Normal AFP does not compensate for an unevaluable liver. [1]

   Reasoning steps for option D

   1. Does sustained HCV clearance erase this patient's established risk?

      No. Prior biopsy-proven cirrhosis remains a surveillance indication; the inadequate ultrasound determines how to perform it.

   2. How do the findings support or oppose this plan: Use AFP surveillance without liver imaging?

      Normal AFP does not compensate for an unevaluable liver. [1]

Takeaway: Cirrhosis-associated risk persists after cure; an MRI-based alternative is reasonable when ultrasound remains severely limited.

Case sources: [1]

1. A. Obtain biopsy because cirrhosis is absent (Why this does not fit)

   Pathology is generally needed outside eligible risk populations, but selected chronic HBV patients can qualify without cirrhosis. His age, sex and endemic origin support that setting. [1]

   Reasoning steps for option A

   1. Does absent cirrhosis prohibit imaging diagnosis in every HBV patient?

      No. This man's chronic HBV risk setting permits the algorithm; the 18 mm enhancement combination then supports definite HCC.

   2. How do the findings support or oppose this plan: Obtain biopsy because cirrhosis is absent?

      Pathology is generally needed outside eligible risk populations, but selected chronic HBV patients can qualify without cirrhosis. His age, sex and endemic origin support that setting. [1]

2. B. Repeat MRI in three months because the lesion is under 2 cm (Why this does not fit)

   In the appropriate population, a 10 to 19 mm lesion with nonrim arterial enhancement and nonperipheral washout can meet LR-5; 2 cm is not a universal minimum. [1,9]

   Reasoning steps for option B

   1. Does absent cirrhosis prohibit imaging diagnosis in every HBV patient?

      No. This man's chronic HBV risk setting permits the algorithm; the 18 mm enhancement combination then supports definite HCC.

   2. How do the findings support or oppose this plan: Repeat MRI in three months because the lesion is under 2 cm?

      In the appropriate population, a 10 to 19 mm lesion with nonrim arterial enhancement and nonperipheral washout can meet LR-5; 2 cm is not a universal minimum. [1,9]

3. C. Use the imaging diagnosis and complete HCC staging (Best answer)

   His chronic HBV risk permits application of noninvasive criteria despite absent cirrhosis. The 18 mm lesion has the required enhancement combination, so complete staging rather than require routine diagnostic biopsy. [1,9]

   Reasoning steps for option C

   1. Does absent cirrhosis prohibit imaging diagnosis in every HBV patient?

      No. This man's chronic HBV risk setting permits the algorithm; the 18 mm enhancement combination then supports definite HCC.

   2. How do the findings support or oppose this plan: Use the imaging diagnosis and complete HCC staging?

      His chronic HBV risk permits application of noninvasive criteria despite absent cirrhosis. The 18 mm lesion has the required enhancement combination, so complete staging rather than require routine diagnostic biopsy. [1,9]

4. D. Return to six-month ultrasound because HBV is suppressed (Why this does not fit)

   Antiviral suppression reduces risk without eliminating it. A diagnostic mass pattern cannot be returned to surveillance solely because viral replication is controlled. [1]

   Reasoning steps for option D

   1. Does absent cirrhosis prohibit imaging diagnosis in every HBV patient?

      No. This man's chronic HBV risk setting permits the algorithm; the 18 mm enhancement combination then supports definite HCC.

   2. How do the findings support or oppose this plan: Return to six-month ultrasound because HBV is suppressed?

      Antiviral suppression reduces risk without eliminating it. A diagnostic mass pattern cannot be returned to surveillance solely because viral replication is controlled. [1]

Takeaway: First establish that the at-risk imaging algorithm applies, then interpret the size and enhancement combination.

Case sources: [1] [9]

1. A. No lesion follow-up or routine HCC surveillance (Best answer)

   The completed MRI shows a confidently typical hemangioma, which does not need lesion-specific follow-up. Separately, F2 metabolic disease without cirrhosis or HBV does not establish an indication for routine HCC surveillance; ongoing liver-disease care continues. [1,8]

   Reasoning steps for option A

   1. Which two decisions follow from the completed MRI and fibrosis history?

      The MRI establishes a typical hemangioma without lesion-specific follow-up. Independently, F2 metabolic fibrosis without HBV or cirrhosis does not justify routine HCC surveillance.

   2. How do the findings support or oppose this plan: No lesion follow-up or routine HCC surveillance?

      The completed MRI shows a confidently typical hemangioma, which does not need lesion-specific follow-up. Separately, F2 metabolic disease without cirrhosis or HBV does not establish an indication for routine HCC surveillance; ongoing liver-disease care continues. [1,8]

2. B. No lesion follow-up; ultrasound and AFP every six months (Why this does not fit)

   This correctly recognizes that a typical hemangioma needs no dedicated follow-up. It incorrectly imports the cirrhosis surveillance schedule into a patient with established F2 fibrosis and no HBV. [1,8]

   Reasoning steps for option B

   1. Which two decisions follow from the completed MRI and fibrosis history?

      The MRI establishes a typical hemangioma without lesion-specific follow-up. Independently, F2 metabolic fibrosis without HBV or cirrhosis does not justify routine HCC surveillance.

   2. How do the findings support or oppose this plan: No lesion follow-up; ultrasound and AFP every six months?

      This correctly recognizes that a typical hemangioma needs no dedicated follow-up. It incorrectly imports the cirrhosis surveillance schedule into a patient with established F2 fibrosis and no HBV. [1,8]

3. C. Liver MRI in three months for continued lesion surveillance (Why this does not fit)

   Short-interval MRI can help characterize an indeterminate lesion. The dedicated examination here already demonstrates a typical benign vascular filling pattern, not an unresolved observation. [8]

   Reasoning steps for option C

   1. Which two decisions follow from the completed MRI and fibrosis history?

      The MRI establishes a typical hemangioma without lesion-specific follow-up. Independently, F2 metabolic fibrosis without HBV or cirrhosis does not justify routine HCC surveillance.

   2. How do the findings support or oppose this plan: Liver MRI in three months for continued lesion surveillance?

      Short-interval MRI can help characterize an indeterminate lesion. The dedicated examination here already demonstrates a typical benign vascular filling pattern, not an unresolved observation. [8]

4. D. Core biopsy now with follow-up directed by histology (Why this does not fit)

   Biopsy can establish the identity of an indeterminate or suspicious mass. The characteristic peripheral nodular filling and persistent blood-pool enhancement establish a typical hemangioma without routine sampling. [8]

   Reasoning steps for option D

   1. Which two decisions follow from the completed MRI and fibrosis history?

      The MRI establishes a typical hemangioma without lesion-specific follow-up. Independently, F2 metabolic fibrosis without HBV or cirrhosis does not justify routine HCC surveillance.

   2. How do the findings support or oppose this plan: Core biopsy now with follow-up directed by histology?

      Biopsy can establish the identity of an indeterminate or suspicious mass. The characteristic peripheral nodular filling and persistent blood-pool enhancement establish a typical hemangioma without routine sampling. [8]

Takeaway: Identify the lesion from complete contrast imaging, then assess surveillance eligibility independently of that lesion.

Case sources: [1] [8]

1. A. Stop HCC surveillance because liver function is poor (Why this does not fit)

   Transplant eligibility preserves potential benefit from detecting an early HCC in a decompensated patient. [1]

   Reasoning steps for option A

   1. Does poor liver function eliminate surveillance in this particular patient?

      No. He remains listed for transplantation; finding a tumor can change candidacy and treatment. The small finding then determines the recall interval.

   2. How do the findings support or oppose this plan: Stop HCC surveillance because liver function is poor?

      Transplant eligibility preserves potential benefit from detecting an early HCC in a decompensated patient. [1]

2. B. Arrange multiphasic CT immediately for the 8-mm observation (Why this does not fit)

   A subcentimeter observation without another recall signal generally undergoes ultrasound follow-up first. [1]

   Reasoning steps for option B

   1. Does poor liver function eliminate surveillance in this particular patient?

      No. He remains listed for transplantation; finding a tumor can change candidacy and treatment. The small finding then determines the recall interval.

   2. How do the findings support or oppose this plan: Arrange multiphasic CT immediately for the 8-mm observation?

      A subcentimeter observation without another recall signal generally undergoes ultrasound follow-up first. [1]

3. C. Measure AFP alone at the next routine visit (Why this does not fit)

   AFP alone neither tracks the nodule nor substitutes for imaging. [1]

   Reasoning steps for option C

   1. Does poor liver function eliminate surveillance in this particular patient?

      No. He remains listed for transplantation; finding a tumor can change candidacy and treatment. The small finding then determines the recall interval.

   2. How do the findings support or oppose this plan: Measure AFP alone at the next routine visit?

      AFP alone neither tracks the nodule nor substitutes for imaging. [1]

4. D. Repeat ultrasound with AFP in 3-6 months (Best answer)

   Transplant eligibility preserves surveillance; the newly detected subcentimeter observation requires a short-interval ultrasound plus AFP recall. [1]

   Reasoning steps for option D

   1. Does poor liver function eliminate surveillance in this particular patient?

      No. He remains listed for transplantation; finding a tumor can change candidacy and treatment. The small finding then determines the recall interval.

   2. How do the findings support or oppose this plan: Repeat ultrasound with AFP in 3-6 months?

      Transplant eligibility preserves surveillance; the newly detected subcentimeter observation requires a short-interval ultrasound plus AFP recall. [1]

Takeaway: Transplant eligibility preserves surveillance; the newly detected subcentimeter observation requires a short-interval ultrasound plus AFP recall.

Case sources: [1]

1. A. Child-Pugh B; ultrasound and AFP every six months (Why this does not fit)

   The laboratory and clinical abnormalities indicate Child-Pugh C, not B. The usual surveillance benefit in Child-Pugh A or B cannot be transferred to transplant-ineligible Child-Pugh C disease. [1,11]

   Reasoning steps for option A

   1. What reserve classification must be established before deciding on surveillance?

      The specified laboratory and clinical components total 14 Child-Pugh points, class C. Because transplantation is unavailable, routine HCC surveillance is not recommended; decompensation and symptom care continue.

   2. How do the findings support or oppose this plan: Child-Pugh B; ultrasound and AFP every six months?

      The laboratory and clinical abnormalities indicate Child-Pugh C, not B. The usual surveillance benefit in Child-Pugh A or B cannot be transferred to transplant-ineligible Child-Pugh C disease. [1,11]

2. B. Child-Pugh C; omit routine HCC surveillance (Best answer)

   The five components give 14 Child-Pugh points: 3 each for bilirubin, albumin, INR and poorly controlled ascites, plus 2 for grade-II encephalopathy. This is class C; without transplant eligibility, routine HCC surveillance is not recommended, while cirrhosis and symptom care continue. [1,11]

   Reasoning steps for option B

   1. What reserve classification must be established before deciding on surveillance?

      The specified laboratory and clinical components total 14 Child-Pugh points, class C. Because transplantation is unavailable, routine HCC surveillance is not recommended; decompensation and symptom care continue.

   2. How do the findings support or oppose this plan: Child-Pugh C; omit routine HCC surveillance?

      The five components give 14 Child-Pugh points: 3 each for bilirubin, albumin, INR and poorly controlled ascites, plus 2 for grade-II encephalopathy. This is class C; without transplant eligibility, routine HCC surveillance is not recommended, while cirrhosis and symptom care continue. [1,11]

3. C. Child-Pugh C; ultrasound and AFP every six months (Why this does not fit)

   The reserve classification is correct, but the surveillance plan ignores transplant ineligibility. Child-Pugh C patients receive HCC surveillance when transplantation is available, not simply because their cancer risk is high. [1]

   Reasoning steps for option C

   1. What reserve classification must be established before deciding on surveillance?

      The specified laboratory and clinical components total 14 Child-Pugh points, class C. Because transplantation is unavailable, routine HCC surveillance is not recommended; decompensation and symptom care continue.

   2. How do the findings support or oppose this plan: Child-Pugh C; ultrasound and AFP every six months?

      The reserve classification is correct, but the surveillance plan ignores transplant ineligibility. Child-Pugh C patients receive HCC surveillance when transplantation is available, not simply because their cancer risk is high. [1]

4. D. Child-Pugh B; omit routine HCC surveillance (Why this does not fit)

   The surveillance decision fits the stated transplant-ineligible severe disease, but the reserve classification does not. The combined laboratory impairment, poorly controlled ascites and encephalopathy place the patient in class C. [1,11]

   Reasoning steps for option D

   1. What reserve classification must be established before deciding on surveillance?

      The specified laboratory and clinical components total 14 Child-Pugh points, class C. Because transplantation is unavailable, routine HCC surveillance is not recommended; decompensation and symptom care continue.

   2. How do the findings support or oppose this plan: Child-Pugh B; omit routine HCC surveillance?

      The surveillance decision fits the stated transplant-ineligible severe disease, but the reserve classification does not. The combined laboratory impairment, poorly controlled ascites and encephalopathy place the patient in class C. [1,11]

Takeaway: Determine reserve from all five Child-Pugh components, then apply the transplant-dependent surveillance exception for class C.

Case sources: [1] [11]

1. A. Definite HCC; complete staging for tumor treatment (Why this does not fit)

   The lesion loses attenuation but remains brighter than liver: differences are +50, +10 and +7 HU. Thus the supplied data do not establish the washout needed to complete this LR-5 pattern. [1,4,9]

   Reasoning steps for option A

   1. Does the lesion become darker than background liver on either later phase?

      No. It remains +10 HU and +7 HU relative to liver, so the falling absolute attenuation does not establish washout.

   2. How do the findings support or oppose this plan: Definite HCC; complete staging for tumor treatment?

      The lesion loses attenuation but remains brighter than liver: differences are +50, +10 and +7 HU. Thus the supplied data do not establish the washout needed to complete this LR-5 pattern. [1,4,9]

2. B. Typical hemangioma; return to routine surveillance (Why this does not fit)

   The described homogeneous arterial enhancement is not the discontinuous peripheral nodular enhancement and progressive filling of a typical hemangioma. [8]

   Reasoning steps for option B

   1. Does the lesion become darker than background liver on either later phase?

      No. It remains +10 HU and +7 HU relative to liver, so the falling absolute attenuation does not establish washout.

   2. How do the findings support or oppose this plan: Typical hemangioma; return to routine surveillance?

      The described homogeneous arterial enhancement is not the discontinuous peripheral nodular enhancement and progressive filling of a typical hemangioma. [8]

3. C. Probable HCC; multidisciplinary follow-up or biopsy (Best answer)

   Subtracting liver from lesion shows persistent positive relative contrast, not washout. A mass at least 2 cm with nonrim arterial hyperenhancement alone is probable rather than definite HCC; multidisciplinary review selects imaging within three months or biopsy. [1,4,9]

   Reasoning steps for option C

   1. Does the lesion become darker than background liver on either later phase?

      No. It remains +10 HU and +7 HU relative to liver, so the falling absolute attenuation does not establish washout.

   2. How do the findings support or oppose this plan: Probable HCC; multidisciplinary follow-up or biopsy?

      Subtracting liver from lesion shows persistent positive relative contrast, not washout. A mass at least 2 cm with nonrim arterial hyperenhancement alone is probable rather than definite HCC; multidisciplinary review selects imaging within three months or biopsy. [1,4,9]

4. D. Malignant-nonspecific pattern; obtain histologic typing (Why this does not fit)

   No targetoid, rim or other LR-M feature is supplied. Missing washout does not by itself establish a malignant-nonspecific category. [1,9]

   Reasoning steps for option D

   1. Does the lesion become darker than background liver on either later phase?

      No. It remains +10 HU and +7 HU relative to liver, so the falling absolute attenuation does not establish washout.

   2. How do the findings support or oppose this plan: Malignant-nonspecific pattern; obtain histologic typing?

      No targetoid, rim or other LR-M feature is supplied. Missing washout does not by itself establish a malignant-nonspecific category. [1,9]

Takeaway: Interpret lesion-to-liver contrast before applying size-dependent diagnostic categories and their management pathways.

Case sources: [1] [4] [8] [9]

1. A. Then: six-month surveillance; now: multiphasic CT or MRI (Best answer)

   Two stable short-interval examinations with reassuring AFP permit return to six-month surveillance. At the later visit, the new AFP elevation above 20 ng/mL warrants diagnostic CT or MRI despite an unchanged subcentimeter observation and otherwise negative ultrasound. [1]

   Reasoning steps for option A

   1. What changes between the earlier stable visits and the current visit?

      Two stable subcentimeter examinations with reassuring AFP permit six-month surveillance. The later AFP rise to 34 ng/mL independently requires diagnostic imaging despite unchanged lesion size.

   2. How do the findings support or oppose this plan: Then: six-month surveillance; now: multiphasic CT or MRI?

      Two stable short-interval examinations with reassuring AFP permit return to six-month surveillance. At the later visit, the new AFP elevation above 20 ng/mL warrants diagnostic CT or MRI despite an unchanged subcentimeter observation and otherwise negative ultrasound. [1]

2. B. Then: three-month surveillance; now: multiphasic CT or MRI (Why this does not fit)

   The current diagnostic imaging choice is appropriate for the new AFP signal. Continuing three-month recall after the earlier two stable examinations was unnecessary when AFP was reassuring. [1]

   Reasoning steps for option B

   1. What changes between the earlier stable visits and the current visit?

      Two stable subcentimeter examinations with reassuring AFP permit six-month surveillance. The later AFP rise to 34 ng/mL independently requires diagnostic imaging despite unchanged lesion size.

   2. How do the findings support or oppose this plan: Then: three-month surveillance; now: multiphasic CT or MRI?

      The current diagnostic imaging choice is appropriate for the new AFP signal. Continuing three-month recall after the earlier two stable examinations was unnecessary when AFP was reassuring. [1]

3. C. Then: six-month surveillance; now: repeat ultrasound in three months (Why this does not fit)

   The earlier return to six-month surveillance is appropriate. The later AFP rise is an independent diagnostic recall signal; another short-interval ultrasound does not substitute for multiphasic characterization. [1]

   Reasoning steps for option C

   1. What changes between the earlier stable visits and the current visit?

      Two stable subcentimeter examinations with reassuring AFP permit six-month surveillance. The later AFP rise to 34 ng/mL independently requires diagnostic imaging despite unchanged lesion size.

   2. How do the findings support or oppose this plan: Then: six-month surveillance; now: repeat ultrasound in three months?

      The earlier return to six-month surveillance is appropriate. The later AFP rise is an independent diagnostic recall signal; another short-interval ultrasound does not substitute for multiphasic characterization. [1]

4. D. Then: three-month surveillance; now: repeat ultrasound in three months (Why this does not fit)

   This keeps the earlier short interval after sufficient stability and then fails to respond to the separate new AFP signal. Stability of one small observation cannot establish that the whole liver remains free of a developing lesion. [1]

   Reasoning steps for option D

   1. What changes between the earlier stable visits and the current visit?

      Two stable subcentimeter examinations with reassuring AFP permit six-month surveillance. The later AFP rise to 34 ng/mL independently requires diagnostic imaging despite unchanged lesion size.

   2. How do the findings support or oppose this plan: Then: three-month surveillance; now: repeat ultrasound in three months?

      This keeps the earlier short interval after sufficient stability and then fails to respond to the separate new AFP signal. Stability of one small observation cannot establish that the whole liver remains free of a developing lesion. [1]

Takeaway: End short-interval recall when stability is established, but reassess the pathway when a separate surveillance signal changes.

Case sources: [1]

1. A. Probable HCC; repeat contrast imaging within three months (Why this does not fit)

   Short-interval reassessment fits some probable-HCC observations, but the 60% increase within four months meets threshold growth. Together with nonrim arterial enhancement at this size, it supports LR-5. [1,9]

   Reasoning steps for option A

   1. How much has the mass grown on comparable MRI?

      The increase is (16-10)/10 = 60% in four months, meeting the at-least-50%-within-six-months diagnostic threshold.

   2. How do the findings support or oppose this plan: Probable HCC; repeat contrast imaging within three months?

      Short-interval reassessment fits some probable-HCC observations, but the 60% increase within four months meets threshold growth. Together with nonrim arterial enhancement at this size, it supports LR-5. [1,9]

2. B. Malignant-nonspecific lesion; obtain biopsy for tumor typing (Why this does not fit)

   No malignant-nonspecific pattern is supplied. Threshold growth of a solid arterialized mass supports the HCC diagnostic pathway rather than automatically assigning LR-M. [1,9]

   Reasoning steps for option B

   1. How much has the mass grown on comparable MRI?

      The increase is (16-10)/10 = 60% in four months, meeting the at-least-50%-within-six-months diagnostic threshold.

   2. How do the findings support or oppose this plan: Malignant-nonspecific lesion; obtain biopsy for tumor typing?

      No malignant-nonspecific pattern is supplied. Threshold growth of a solid arterialized mass supports the HCC diagnostic pathway rather than automatically assigning LR-M. [1,9]

3. C. Indeterminate observation; repeat contrast MRI in six months (Why this does not fit)

   A 60% diameter increase on comparable MRI within four months meets threshold growth. In an eligible cirrhotic patient, that finding plus nonrim arterial hyperenhancement in a 16-mm mass supports LR-5, rather than a six-month indeterminate-observation pathway. [1,9]

   Reasoning steps for option C

   1. How much has the mass grown on comparable MRI?

      The increase is (16-10)/10 = 60% in four months, meeting the at-least-50%-within-six-months diagnostic threshold.

   2. How do the findings support or oppose this plan: Indeterminate observation; repeat contrast MRI in six months?

      A 60% diameter increase on comparable MRI within four months meets threshold growth. In an eligible cirrhotic patient, that finding plus nonrim arterial hyperenhancement in a 16-mm mass supports LR-5, rather than a six-month indeterminate-observation pathway. [1,9]

4. D. Definite HCC; complete staging and assess treatment eligibility (Best answer)

   Growth is (16-10)/10 = 60% within four months, exceeding the CT/MRI threshold of at least 50% within six months. In this cirrhotic patient, nonrim arterial enhancement plus qualifying growth at 16 mm supports LR-5 and subsequent staging. [1,9]

   Reasoning steps for option D

   1. How much has the mass grown on comparable MRI?

      The increase is (16-10)/10 = 60% in four months, meeting the at-least-50%-within-six-months diagnostic threshold.

   2. How do the findings support or oppose this plan: Definite HCC; complete staging and assess treatment eligibility?

      Growth is (16-10)/10 = 60% within four months, exceeding the CT/MRI threshold of at least 50% within six months. In this cirrhotic patient, nonrim arterial enhancement plus qualifying growth at 16 mm supports LR-5 and subsequent staging. [1,9]

Takeaway: Calculate growth on comparable diagnostic studies, then combine it with population, size and enhancement before assigning a category.

Case sources: [1] [9]

1. A. AFP confirms HCC; biopsy assesses tumor differentiation (Why this does not fit)

   The AFP trend justified diagnostic imaging but does not establish HCC, particularly with a competing inflammatory cause. The targetoid mass needs biopsy to determine tumor type, not merely to grade an already proven HCC. [1,7,9]

   Reasoning steps for option A

   1. Does the AFP series or MRI establish an HCC-specific diagnosis?

      No. AFP prompts diagnostic recall but is not diagnostic; rim and targetoid enhancement identify a malignant-nonspecific pattern requiring tissue typing.

   2. How do the findings support or oppose this plan: AFP confirms HCC; biopsy assesses tumor differentiation?

      The AFP trend justified diagnostic imaging but does not establish HCC, particularly with a competing inflammatory cause. The targetoid mass needs biopsy to determine tumor type, not merely to grade an already proven HCC. [1,7,9]

2. B. AFP reflects hepatitis; repeat ultrasound after six months (Why this does not fit)

   Hepatitis can raise AFP, but it cannot safely explain away the consecutive increases or the subsequently detected malignant-appearing mass. Six-month surveillance leaves the tumor identity unresolved. [1,7]

   Reasoning steps for option B

   1. Does the AFP series or MRI establish an HCC-specific diagnosis?

      No. AFP prompts diagnostic recall but is not diagnostic; rim and targetoid enhancement identify a malignant-nonspecific pattern requiring tissue typing.

   2. How do the findings support or oppose this plan: AFP reflects hepatitis; repeat ultrasound after six months?

      Hepatitis can raise AFP, but it cannot safely explain away the consecutive increases or the subsequently detected malignant-appearing mass. Six-month surveillance leaves the tumor identity unresolved. [1,7]

3. C. AFP triggers recall; biopsy establishes the tumor type (Best answer)

   The rising AFP is a diagnostic recall signal rather than proof of cancer type. Rim and targetoid enhancement support an LR-M-type observation; biopsy distinguishes HCC from other primary or secondary malignancies before selecting tumor-specific treatment. [1,9]

   Reasoning steps for option C

   1. Does the AFP series or MRI establish an HCC-specific diagnosis?

      No. AFP prompts diagnostic recall but is not diagnostic; rim and targetoid enhancement identify a malignant-nonspecific pattern requiring tissue typing.

   2. How do the findings support or oppose this plan: AFP triggers recall; biopsy establishes the tumor type?

      The rising AFP is a diagnostic recall signal rather than proof of cancer type. Rim and targetoid enhancement support an LR-M-type observation; biopsy distinguishes HCC from other primary or secondary malignancies before selecting tumor-specific treatment. [1,9]

4. D. AFP triggers recall; ablation treats imaging-established HCC (Why this does not fit)

   The interpretation of AFP as a recall signal is appropriate. The MRI is not an HCC-specific LR-5 pattern, so an HCC-directed ablation plan would assume the histologic identity that still needs to be established. [1,9]

   Reasoning steps for option D

   1. Does the AFP series or MRI establish an HCC-specific diagnosis?

      No. AFP prompts diagnostic recall but is not diagnostic; rim and targetoid enhancement identify a malignant-nonspecific pattern requiring tissue typing.

   2. How do the findings support or oppose this plan: AFP triggers recall; ablation treats imaging-established HCC?

      The interpretation of AFP as a recall signal is appropriate. The MRI is not an HCC-specific LR-5 pattern, so an HCC-directed ablation plan would assume the histologic identity that still needs to be established. [1,9]

Takeaway: Interpret AFP as a reason to investigate, then use the actual imaging pattern to decide whether tumor typing requires tissue.

Case sources: [1] [7] [9]

1. A. Assign definite imaging HCC and proceed to reserve assessment (Best answer)

   The at-risk setting, size and major imaging features can establish HCC noninvasively; reserve still guides treatment. [1]

   Reasoning steps for option A

   1. Which combination establishes imaging specificity here?

      Cirrhosis plus a lesion larger than 2 cm with nonrim arterial enhancement and nonperipheral washout supports definite HCC; normal AFP does not negate it.

   2. How do the findings support or oppose this plan: Assign definite imaging HCC and proceed to reserve assessment?

      The at-risk setting, size and major imaging features can establish HCC noninvasively; reserve still guides treatment. [1]

2. B. Classify as probably HCC and repeat MRI within three months (Why this does not fit)

   Short-interval imaging is appropriate for some LR-4 observations, but this at-risk patient has a lesion larger than 2 cm with nonrim arterial hyperenhancement and nonperipheral washout, supporting LR-5. [1]

   Reasoning steps for option B

   1. Which combination establishes imaging specificity here?

      Cirrhosis plus a lesion larger than 2 cm with nonrim arterial enhancement and nonperipheral washout supports definite HCC; normal AFP does not negate it.

   2. How do the findings support or oppose this plan: Classify as probably HCC and repeat MRI within three months?

      Short-interval imaging is appropriate for some LR-4 observations, but this at-risk patient has a lesion larger than 2 cm with nonrim arterial hyperenhancement and nonperipheral washout, supporting LR-5. [1]

3. C. Repeat ultrasound after six months to confirm persistence (Why this does not fit)

   A diagnostic lesion needs staging and liver assessment, not routine surveillance. [1]

   Reasoning steps for option C

   1. Which combination establishes imaging specificity here?

      Cirrhosis plus a lesion larger than 2 cm with nonrim arterial enhancement and nonperipheral washout supports definite HCC; normal AFP does not negate it.

   2. How do the findings support or oppose this plan: Repeat ultrasound after six months to confirm persistence?

      A diagnostic lesion needs staging and liver assessment, not routine surveillance. [1]

4. D. Require biopsy because the serum marker is normal (Why this does not fit)

   Normal AFP does not invalidate qualifying LR-5 imaging features. [1]

   Reasoning steps for option D

   1. Which combination establishes imaging specificity here?

      Cirrhosis plus a lesion larger than 2 cm with nonrim arterial enhancement and nonperipheral washout supports definite HCC; normal AFP does not negate it.

   2. How do the findings support or oppose this plan: Require biopsy because the serum marker is normal?

      Normal AFP does not invalidate qualifying LR-5 imaging features. [1]

Takeaway: The at-risk setting, size and major imaging features can establish HCC noninvasively; reserve still guides treatment.

Case sources: [1]

1. A. Obtain core biopsy before choosing lesion follow-up (Why this does not fit)

   Routine core biopsy is not needed for a confidently typical hemangioma on complete contrast imaging. Obtain tissue when the diagnosis remains uncertain, not solely because cirrhosis raises background HCC risk. [1,8]

   Reasoning steps for option A

   1. What spatial enhancement behavior distinguishes this lesion?

      Discontinuous peripheral nodules with centripetal filling and persistent blood-pool brightness favor hemangioma, not the characteristic HCC pattern.

   2. How do the findings support or oppose this plan: Obtain core biopsy before choosing lesion follow-up?

      Routine core biopsy is not needed for a confidently typical hemangioma on complete contrast imaging. Obtain tissue when the diagnosis remains uncertain, not solely because cirrhosis raises background HCC risk. [1,8]

2. B. Treat the lesion as HCC and initiate staging (Why this does not fit)

   Progressive centripetal blood-pool filling differs from HCC nonrim enhancement and washout. [1] [8]

   Reasoning steps for option B

   1. What spatial enhancement behavior distinguishes this lesion?

      Discontinuous peripheral nodules with centripetal filling and persistent blood-pool brightness favor hemangioma, not the characteristic HCC pattern.

   2. How do the findings support or oppose this plan: Treat the lesion as HCC and initiate staging?

      Progressive centripetal blood-pool filling differs from HCC nonrim enhancement and washout. [1] [8]

3. C. Repeat contrast MRI in three months before assigning benignity (Why this does not fit)

   Short-interval contrast imaging is appropriate for an unresolved observation. The clearly typical peripheral nodular filling pattern here already establishes a benign hemangioma; the separate cirrhosis risk still requires HCC surveillance. [1,8]

   Reasoning steps for option C

   1. What spatial enhancement behavior distinguishes this lesion?

      Discontinuous peripheral nodules with centripetal filling and persistent blood-pool brightness favor hemangioma, not the characteristic HCC pattern.

   2. How do the findings support or oppose this plan: Repeat contrast MRI in three months before assigning benignity?

      Short-interval contrast imaging is appropriate for an unresolved observation. The clearly typical peripheral nodular filling pattern here already establishes a benign hemangioma; the separate cirrhosis risk still requires HCC surveillance. [1,8]

4. D. Continue cirrhosis surveillance without dedicated lesion imaging (Best answer)

   This is a typical hemangioma requiring no lesion-specific cancer follow-up, while cirrhosis still warrants surveillance. [1] [8]

   Reasoning steps for option D

   1. What spatial enhancement behavior distinguishes this lesion?

      Discontinuous peripheral nodules with centripetal filling and persistent blood-pool brightness favor hemangioma, not the characteristic HCC pattern.

   2. How do the findings support or oppose this plan: Continue cirrhosis surveillance without dedicated lesion imaging?

      This is a typical hemangioma requiring no lesion-specific cancer follow-up, while cirrhosis still warrants surveillance. [1] [8]

Takeaway: This is a typical hemangioma requiring no lesion-specific cancer follow-up, while cirrhosis still warrants surveillance.

Case sources: [1] [8]

1. A. Definite HCC; begin treatment without further characterization (Why this does not fit)

   Arterial enhancement without an additional defining feature does not suffice for LR-5. [1]

   Reasoning steps for option A

   1. What category remains when arterial enhancement lacks other major or ancillary malignant features?

      A 14 mm observation with the specified isolated feature fits LR-3 rather than LR-5.

   2. How do the findings support or oppose this plan: Definite HCC; begin treatment without further characterization?

      Arterial enhancement without an additional defining feature does not suffice for LR-5. [1]

2. B. Indeterminate LR-3; repeat multiphasic imaging in 3-6 months (Best answer)

   An isolated small arterialized observation is indeterminate; interval cross-sectional imaging is appropriate. [1]

   Reasoning steps for option B

   1. What category remains when arterial enhancement lacks other major or ancillary malignant features?

      A 14 mm observation with the specified isolated feature fits LR-3 rather than LR-5.

   2. How do the findings support or oppose this plan: Indeterminate LR-3; repeat multiphasic imaging in 3-6 months?

      An isolated small arterialized observation is indeterminate; interval cross-sectional imaging is appropriate. [1]

3. C. Probably HCC LR-4; discuss biopsy with the multidisciplinary team (Why this does not fit)

   An isolated 14-mm nonrim arterial-hyperenhancing observation without another qualifying major or ancillary feature is LR-3, not LR-4. Biopsy can be discussed for LR-4 in context, but this case supports repeat multiphasic imaging in 3-6 months. [1,9]

   Reasoning steps for option C

   1. What category remains when arterial enhancement lacks other major or ancillary malignant features?

      A 14 mm observation with the specified isolated feature fits LR-3 rather than LR-5.

   2. How do the findings support or oppose this plan: Probably HCC LR-4; discuss biopsy with the multidisciplinary team?

      An isolated 14-mm nonrim arterial-hyperenhancing observation without another qualifying major or ancillary feature is LR-3, not LR-4. Biopsy can be discussed for LR-4 in context, but this case supports repeat multiphasic imaging in 3-6 months. [1,9]

4. D. Benign LR-1; resume routine ultrasound surveillance (Why this does not fit)

   An arterialized observation is not confidently benign. [1]

   Reasoning steps for option D

   1. What category remains when arterial enhancement lacks other major or ancillary malignant features?

      A 14 mm observation with the specified isolated feature fits LR-3 rather than LR-5.

   2. How do the findings support or oppose this plan: Benign LR-1; resume routine ultrasound surveillance?

      An arterialized observation is not confidently benign. [1]

Takeaway: An isolated small arterialized observation is indeterminate; interval cross-sectional imaging is appropriate.

Case sources: [1] [9]

1. A. Definite HCC; complete staging and begin treatment planning (Why this does not fit)

   Capsule plus arterial enhancement at 15 mm does not establish LR-5. [1]

   Reasoning steps for option A

   1. Does an enhancing capsule finish the diagnosis at 15 mm?

      No. With arterial enhancement but no washout or threshold growth, the supplied findings support probable rather than definite HCC.

   2. How do the findings support or oppose this plan: Definite HCC; complete staging and begin treatment planning?

      Capsule plus arterial enhancement at 15 mm does not establish LR-5. [1]

2. B. Benign observation; continue surveillance with ultrasound and AFP (Why this does not fit)

   An enhancing nodule with a capsule is not benign by default. [1]

   Reasoning steps for option B

   1. Does an enhancing capsule finish the diagnosis at 15 mm?

      No. With arterial enhancement but no washout or threshold growth, the supplied findings support probable rather than definite HCC.

   2. How do the findings support or oppose this plan: Benign observation; continue surveillance with ultrasound and AFP?

      An enhancing nodule with a capsule is not benign by default. [1]

3. C. Probable HCC; repeat contrast imaging within three months (Best answer)

   This 10-19-mm pattern is suspicious but lacks LR-5 criteria; multidisciplinary review can favor short-interval imaging when tissue has no immediate management impact. [1]

   Reasoning steps for option C

   1. Does an enhancing capsule finish the diagnosis at 15 mm?

      No. With arterial enhancement but no washout or threshold growth, the supplied findings support probable rather than definite HCC.

   2. How do the findings support or oppose this plan: Probable HCC; repeat contrast imaging within three months?

      This 10-19-mm pattern is suspicious but lacks LR-5 criteria; multidisciplinary review can favor short-interval imaging when tissue has no immediate management impact. [1]

4. D. Malignant-nonspecific observation; obtain tissue to establish tumor type (Why this does not fit)

   The described lesion lacks a targetoid or rim pattern. [1]

   Reasoning steps for option D

   1. Does an enhancing capsule finish the diagnosis at 15 mm?

      No. With arterial enhancement but no washout or threshold growth, the supplied findings support probable rather than definite HCC.

   2. How do the findings support or oppose this plan: Malignant-nonspecific observation; obtain tissue to establish tumor type?

      The described lesion lacks a targetoid or rim pattern. [1]

Takeaway: This 10-19-mm pattern is suspicious but lacks LR-5 criteria; multidisciplinary review can favor short-interval imaging when tissue has no immediate management impact.

Case sources: [1]

1. A. Classify HCC from cirrhosis and lesion size (Why this does not fit)

   Neither cirrhosis nor diameter makes a targetoid lesion HCC-specific. [1]

   Reasoning steps for option A

   1. What does the targetoid pattern establish, and what does it leave uncertain?

      It raises concern for malignancy not specific for HCC. The histologic tumor type remains unresolved.

   2. How do the findings support or oppose this plan: Classify HCC from cirrhosis and lesion size?

      Neither cirrhosis nor diameter makes a targetoid lesion HCC-specific. [1]

2. B. Observe with routine ultrasound in six months (Why this does not fit)

   A malignant-appearing targetoid lesion warrants more than routine surveillance. [1]

   Reasoning steps for option B

   1. What does the targetoid pattern establish, and what does it leave uncertain?

      It raises concern for malignancy not specific for HCC. The histologic tumor type remains unresolved.

   2. How do the findings support or oppose this plan: Observe with routine ultrasound in six months?

      A malignant-appearing targetoid lesion warrants more than routine surveillance. [1]

3. C. Diagnose intrahepatic cholangiocarcinoma without tissue (Why this does not fit)

   The targetoid pattern raises concern for a non-HCC malignancy, but it cannot distinguish cholangiocarcinoma from combined tumors or atypical HCC with certainty. Tissue addresses that uncertainty. [1,9]

   Reasoning steps for option C

   1. What does the targetoid pattern establish, and what does it leave uncertain?

      It raises concern for malignancy not specific for HCC. The histologic tumor type remains unresolved.

   2. How do the findings support or oppose this plan: Diagnose intrahepatic cholangiocarcinoma without tissue?

      The targetoid pattern raises concern for a non-HCC malignancy, but it cannot distinguish cholangiocarcinoma from combined tumors or atypical HCC with certainty. Tissue addresses that uncertainty. [1,9]

4. D. Obtain an image-guided biopsy for histologic diagnosis (Best answer)

   The LR-M-type pattern suggests malignancy without HCC specificity; tissue establishes tumor type. [1]

   Reasoning steps for option D

   1. What does the targetoid pattern establish, and what does it leave uncertain?

      It raises concern for malignancy not specific for HCC. The histologic tumor type remains unresolved.

   2. How do the findings support or oppose this plan: Obtain an image-guided biopsy for histologic diagnosis?

      The LR-M-type pattern suggests malignancy without HCC specificity; tissue establishes tumor type. [1]

Takeaway: The LR-M-type pattern suggests malignancy without HCC specificity; tissue establishes tumor type.

Case sources: [1] [9]

1. A. Tissue diagnosis after multidisciplinary staging review (Best answer)

   The enhancement pattern outside the eligible at-risk population cannot securely identify tumor type; pathology is generally required. [1]

   Reasoning steps for option A

   1. Can the usual at-risk imaging-only diagnosis be applied to this person?

      No. He has neither cirrhosis nor chronic HBV, and prior colon cancer creates a competing origin that imaging alone has not resolved.

   2. How do the findings support or oppose this plan: Tissue diagnosis after multidisciplinary staging review?

      The enhancement pattern outside the eligible at-risk population cannot securely identify tumor type; pathology is generally required. [1]

2. B. Assign definite HCC using an at-risk LI-RADS algorithm (Why this does not fit)

   Noninvasive LR-5 criteria are not validated for this noncirrhotic, HBV-negative context. [1]

   Reasoning steps for option B

   1. Can the usual at-risk imaging-only diagnosis be applied to this person?

      No. He has neither cirrhosis nor chronic HBV, and prior colon cancer creates a competing origin that imaging alone has not resolved.

   2. How do the findings support or oppose this plan: Assign definite HCC using an at-risk LI-RADS algorithm?

      Noninvasive LR-5 criteria are not validated for this noncirrhotic, HBV-negative context. [1]

3. C. Use an isolated AFP value to establish tumor origin (Why this does not fit)

   AFP alone cannot reliably establish HCC or exclude metastasis. [1]

   Reasoning steps for option C

   1. Can the usual at-risk imaging-only diagnosis be applied to this person?

      No. He has neither cirrhosis nor chronic HBV, and prior colon cancer creates a competing origin that imaging alone has not resolved.

   2. How do the findings support or oppose this plan: Use an isolated AFP value to establish tumor origin?

      AFP alone cannot reliably establish HCC or exclude metastasis. [1]

4. D. Repeat MRI in six months to establish tumor origin (Why this does not fit)

   Persistence of the same pattern does not establish histologic identity. [1]

   Reasoning steps for option D

   1. Can the usual at-risk imaging-only diagnosis be applied to this person?

      No. He has neither cirrhosis nor chronic HBV, and prior colon cancer creates a competing origin that imaging alone has not resolved.

   2. How do the findings support or oppose this plan: Repeat MRI in six months to establish tumor origin?

      Persistence of the same pattern does not establish histologic identity. [1]

Takeaway: The enhancement pattern outside the eligible at-risk population cannot securely identify tumor type; pathology is generally required.

Case sources: [1]

1. A. List directly under standard Milan tumor limits (Why this does not fit)

   With three tumors, the 3.3-cm lesion exceeds the standard per-lesion Milan limit of 3 cm. [1]

   Reasoning steps for option A

   1. Do three lesions measuring 2.1, 2.4 and 3.3 cm meet standard Milan limits?

      No. With up to three lesions, each must be no larger than 3 cm. The 3.3 cm lesion exceeds that limit.

   2. How do the findings support or oppose this plan: List directly under standard Milan tumor limits?

      With three tumors, the 3.3-cm lesion exceeds the standard per-lesion Milan limit of 3 cm. [1]

2. B. Use downstaging therapy before reassessing transplant eligibility (Best answer)

   The patient is outside standard Milan limits yet may be considered for selected downstaging and subsequent reassessment, not automatic listing. [1]

   Reasoning steps for option B

   1. Do three lesions measuring 2.1, 2.4 and 3.3 cm meet standard Milan limits?

      No. With up to three lesions, each must be no larger than 3 cm. The 3.3 cm lesion exceeds that limit.

   2. How do the findings support or oppose this plan: Use downstaging therapy before reassessing transplant eligibility?

      The patient is outside standard Milan limits yet may be considered for selected downstaging and subsequent reassessment, not automatic listing. [1]

3. C. Exclude transplant consideration and begin systemic therapy (Why this does not fit)

   One of three lesions exceeds 3 cm, so the burden is outside standard Milan limits. That does not automatically foreclose transplantation: selected downstaging is feasible with the stated reserve and absence of spread. [1]

   Reasoning steps for option C

   1. Do three lesions measuring 2.1, 2.4 and 3.3 cm meet standard Milan limits?

      No. With up to three lesions, each must be no larger than 3 cm. The 3.3 cm lesion exceeds that limit.

   2. How do the findings support or oppose this plan: Exclude transplant consideration and begin systemic therapy?

      One of three lesions exceeds 3 cm, so the burden is outside standard Milan limits. That does not automatically foreclose transplantation: selected downstaging is feasible with the stated reserve and absence of spread. [1]

4. D. Begin liver-directed therapy without further transplant assessment (Why this does not fit)

   Liver-directed therapy can be part of downstaging, but ending transplant assessment would miss a potential curative pathway. The tumors exceed Milan because one is over 3 cm yet have a 7.8-cm total diameter within commonly used selected downstaging entry limits; listing still depends on response and other criteria. [1]

   Reasoning steps for option D

   1. Do three lesions measuring 2.1, 2.4 and 3.3 cm meet standard Milan limits?

      No. With up to three lesions, each must be no larger than 3 cm. The 3.3 cm lesion exceeds that limit.

   2. How do the findings support or oppose this plan: Begin liver-directed therapy without further transplant assessment?

      Liver-directed therapy can be part of downstaging, but ending transplant assessment would miss a potential curative pathway. The tumors exceed Milan because one is over 3 cm yet have a 7.8-cm total diameter within commonly used selected downstaging entry limits; listing still depends on response and other criteria. [1]

Takeaway: The patient is outside standard Milan limits yet may be considered for selected downstaging and subsequent reassessment, not automatic listing.

Case sources: [1]

1. A. Percutaneous thermal tumor ablation (Why this does not fit)

   Thermal ablation is less reliably curative at 4 cm than for tumors no larger than 3 cm. [1]

   Reasoning steps for option A

   1. What do the liver measurements and portal findings imply about operative reserve?

      Normal bilirubin, albumin and INR, absent ascites and varices, and an adequate remnant support resection assessment for the localized 4 cm tumor.

   2. How do the findings support or oppose this plan: Percutaneous thermal tumor ablation?

      Thermal ablation is less reliably curative at 4 cm than for tumors no larger than 3 cm. [1]

2. B. Selective transarterial chemoembolization (Why this does not fit)

   TACE is generally not preferred over feasible curative surgery for this solitary tumor. [1]

   Reasoning steps for option B

   1. What do the liver measurements and portal findings imply about operative reserve?

      Normal bilirubin, albumin and INR, absent ascites and varices, and an adequate remnant support resection assessment for the localized 4 cm tumor.

   2. How do the findings support or oppose this plan: Selective transarterial chemoembolization?

      TACE is generally not preferred over feasible curative surgery for this solitary tumor. [1]

3. C. Hepatic resection of the tumor (Best answer)

   Favorable synthetic function, absent portal-hypertension evidence and adequate remnant support resection. [1]

   Reasoning steps for option C

   1. What do the liver measurements and portal findings imply about operative reserve?

      Normal bilirubin, albumin and INR, absent ascites and varices, and an adequate remnant support resection assessment for the localized 4 cm tumor.

   2. How do the findings support or oppose this plan: Hepatic resection of the tumor?

      Favorable synthetic function, absent portal-hypertension evidence and adequate remnant support resection. [1]

4. D. Orthotopic liver transplantation (Why this does not fit)

   Transplantation is not automatically preferred when safe resection is feasible. [1]

   Reasoning steps for option D

   1. What do the liver measurements and portal findings imply about operative reserve?

      Normal bilirubin, albumin and INR, absent ascites and varices, and an adequate remnant support resection assessment for the localized 4 cm tumor.

   2. How do the findings support or oppose this plan: Orthotopic liver transplantation?

      Transplantation is not automatically preferred when safe resection is feasible. [1]

Takeaway: Favorable synthetic function, absent portal-hypertension evidence and adequate remnant support resection.

Case sources: [1]

1. A. Limited hepatic resection (Why this does not fit)

   Varices, thrombocytopenia and prior bleeding suggest clinically significant portal hypertension despite normal bilirubin, raising resection risk. [1]

   Reasoning steps for option A

   1. What do varices, splenomegaly and low platelets imply despite normal bilirubin?

      They indicate clinically important portal hypertension; normal bilirubin alone does not establish a low-risk resection profile.

   2. How do the findings support or oppose this plan: Limited hepatic resection?

      Varices, thrombocytopenia and prior bleeding suggest clinically significant portal hypertension despite normal bilirubin, raising resection risk. [1]

2. B. Percutaneous tumor ablation (Why this does not fit)

   Ablation treats the cancer but does not address portal hypertensive cirrhosis in this transplant candidate. [1]

   Reasoning steps for option B

   1. What do varices, splenomegaly and low platelets imply despite normal bilirubin?

      They indicate clinically important portal hypertension; normal bilirubin alone does not establish a low-risk resection profile.

   2. How do the findings support or oppose this plan: Percutaneous tumor ablation?

      Ablation treats the cancer but does not address portal hypertensive cirrhosis in this transplant candidate. [1]

3. C. Transarterial chemoembolization (Why this does not fit)

   Embolization may serve a bridging role but is not the definitive solution for both liver disease and early HCC. [1]

   Reasoning steps for option C

   1. What do varices, splenomegaly and low platelets imply despite normal bilirubin?

      They indicate clinically important portal hypertension; normal bilirubin alone does not establish a low-risk resection profile.

   2. How do the findings support or oppose this plan: Transarterial chemoembolization?

      Embolization may serve a bridging role but is not the definitive solution for both liver disease and early HCC. [1]

4. D. Orthotopic liver transplantation (Best answer)

   The tumor meets Milan criteria and the raw portal-hypertension findings favor transplant assessment, with bridging individualized. [1]

   Reasoning steps for option D

   1. What do varices, splenomegaly and low platelets imply despite normal bilirubin?

      They indicate clinically important portal hypertension; normal bilirubin alone does not establish a low-risk resection profile.

   2. How do the findings support or oppose this plan: Orthotopic liver transplantation?

      The tumor meets Milan criteria and the raw portal-hypertension findings favor transplant assessment, with bridging individualized. [1]

Takeaway: The tumor meets Milan criteria and the raw portal-hypertension findings favor transplant assessment, with bridging individualized.

Case sources: [1]

1. A. Proceed to percutaneous thermal ablation (Best answer)

   The cirrhotic setting, lesion size and qualifying enhancement pattern can establish HCC without routine diagnostic biopsy despite normal AFP. Its small size and favorable location support curative-intent thermal ablation when surgery is unsuitable. [1,3]

   Reasoning steps for option A

   1. Does tissue have to precede selection of local treatment here?

      The eligible cirrhotic setting and qualifying enhancement pattern establish HCC without routine biopsy. Tumor size, accessible location and operative risk then favor thermal ablation.

   2. How do the findings support or oppose this plan: Proceed to percutaneous thermal ablation?

      The cirrhotic setting, lesion size and qualifying enhancement pattern can establish HCC without routine diagnostic biopsy despite normal AFP. Its small size and favorable location support curative-intent thermal ablation when surgery is unsuitable. [1,3]

2. B. Obtain diagnostic biopsy before local treatment (Why this does not fit)

   Biopsy is important outside an eligible imaging population or when tumor identity remains uncertain. This lesion meets noninvasive criteria in cirrhosis, so routine diagnostic tissue is not a prerequisite to the indicated local treatment. [1]

   Reasoning steps for option B

   1. Does tissue have to precede selection of local treatment here?

      The eligible cirrhotic setting and qualifying enhancement pattern establish HCC without routine biopsy. Tumor size, accessible location and operative risk then favor thermal ablation.

   2. How do the findings support or oppose this plan: Obtain diagnostic biopsy before local treatment?

      Biopsy is important outside an eligible imaging population or when tumor identity remains uncertain. This lesion meets noninvasive criteria in cirrhosis, so routine diagnostic tissue is not a prerequisite to the indicated local treatment. [1]

3. C. Proceed to transarterial chemoembolization (Why this does not fit)

   Transarterial treatment is useful for appropriate liver-limited disease or selected bridging. For this solitary 2-cm tumor, feasible curative-intent ablation is preferred over default chemoembolization. [1]

   Reasoning steps for option C

   1. Does tissue have to precede selection of local treatment here?

      The eligible cirrhotic setting and qualifying enhancement pattern establish HCC without routine biopsy. Tumor size, accessible location and operative risk then favor thermal ablation.

   2. How do the findings support or oppose this plan: Proceed to transarterial chemoembolization?

      Transarterial treatment is useful for appropriate liver-limited disease or selected bridging. For this solitary 2-cm tumor, feasible curative-intent ablation is preferred over default chemoembolization. [1]

4. D. Proceed to stereotactic body radiation (Why this does not fit)

   Radiation can be an alternative when thermal treatment is unsuitable. The small tumor, separation from vulnerable structures and available percutaneous approach favor thermal ablation in this patient. [1,3]

   Reasoning steps for option D

   1. Does tissue have to precede selection of local treatment here?

      The eligible cirrhotic setting and qualifying enhancement pattern establish HCC without routine biopsy. Tumor size, accessible location and operative risk then favor thermal ablation.

   2. How do the findings support or oppose this plan: Proceed to stereotactic body radiation?

      Radiation can be an alternative when thermal treatment is unsuitable. The small tumor, separation from vulnerable structures and available percutaneous approach favor thermal ablation in this patient. [1,3]

Takeaway: First establish whether imaging supplies the diagnosis, then use tumor geometry and operative risk to select curative local treatment.

Case sources: [1] [3]

1. A. Hepatic resection of both liver tumors (Why this does not fit)

   Recurrent ascites and low albumin indicate substantial post-resection risk. [1]

   Reasoning steps for option A

   1. How do tumor burden and background liver point in the same direction?

      Two lesions under 3 cm without spread fit standard tumor limits, while recurrent ascites and poor laboratory reserve make the cirrhotic liver itself a treatment target.

   2. How do the findings support or oppose this plan: Hepatic resection of both liver tumors?

      Recurrent ascites and low albumin indicate substantial post-resection risk. [1]

2. B. Liver transplantation for definitive treatment (Best answer)

   Both lesions are within Milan limits; transplant addresses early HCC and decompensated cirrhosis, with bridging considered according to reserve and wait. [1]

   Reasoning steps for option B

   1. How do tumor burden and background liver point in the same direction?

      Two lesions under 3 cm without spread fit standard tumor limits, while recurrent ascites and poor laboratory reserve make the cirrhotic liver itself a treatment target.

   2. How do the findings support or oppose this plan: Liver transplantation for definitive treatment?

      Both lesions are within Milan limits; transplant addresses early HCC and decompensated cirrhosis, with bridging considered according to reserve and wait. [1]

3. C. Thermal ablation of both liver tumors (Why this does not fit)

   Ablation may control small tumors but does not repair hepatic decompensation. [1]

   Reasoning steps for option C

   1. How do tumor burden and background liver point in the same direction?

      Two lesions under 3 cm without spread fit standard tumor limits, while recurrent ascites and poor laboratory reserve make the cirrhotic liver itself a treatment target.

   2. How do the findings support or oppose this plan: Thermal ablation of both liver tumors?

      Ablation may control small tumors but does not repair hepatic decompensation. [1]

4. D. Transarterial treatment of both liver tumors (Why this does not fit)

   Transarterial treatment may be used selectively as a bridge but cannot replace a viable transplant pathway. [1]

   Reasoning steps for option D

   1. How do tumor burden and background liver point in the same direction?

      Two lesions under 3 cm without spread fit standard tumor limits, while recurrent ascites and poor laboratory reserve make the cirrhotic liver itself a treatment target.

   2. How do the findings support or oppose this plan: Transarterial treatment of both liver tumors?

      Transarterial treatment may be used selectively as a bridge but cannot replace a viable transplant pathway. [1]

Takeaway: Both lesions are within Milan limits; transplant addresses early HCC and decompensated cirrhosis, with bridging considered according to reserve and wait.

Case sources: [1]

1. A. Treat as bland thrombosis and preserve routine transplant listing (Why this does not fit)

   Enhancing contiguous soft tissue favors tumor in vein, not bland clot. [1]

   Reasoning steps for option A

   1. Why is the venous finding more concerning than an isolated filling defect?

      Arterially enhancing soft tissue continuous with HCC favors tumor in vein, which changes stage despite the small parenchymal tumor.

   2. How do the findings support or oppose this plan: Treat as bland thrombosis and preserve routine transplant listing?

      Enhancing contiguous soft tissue favors tumor in vein, not bland clot. [1]

2. B. Proceed with ablation of the parenchymal mass alone (Why this does not fit)

   Treating the mass alone leaves major vascular disease untreated. [1]

   Reasoning steps for option B

   1. Why is the venous finding more concerning than an isolated filling defect?

      Arterially enhancing soft tissue continuous with HCC favors tumor in vein, which changes stage despite the small parenchymal tumor.

   2. How do the findings support or oppose this plan: Proceed with ablation of the parenchymal mass alone?

      Treating the mass alone leaves major vascular disease untreated. [1]

3. C. Treat as macrovascular invasion and evaluate systemic therapy (Best answer)

   Likely tumor in vein changes stage and generally excludes standard transplant eligibility; systemic treatment is considered with adequate reserve. [1]

   Reasoning steps for option C

   1. Why is the venous finding more concerning than an isolated filling defect?

      Arterially enhancing soft tissue continuous with HCC favors tumor in vein, which changes stage despite the small parenchymal tumor.

   2. How do the findings support or oppose this plan: Treat as macrovascular invasion and evaluate systemic therapy?

      Likely tumor in vein changes stage and generally excludes standard transplant eligibility; systemic treatment is considered with adequate reserve. [1]

4. D. Treat as intermediate-stage disease with routine TACE (Why this does not fit)

   Enhancing intravascular tissue continuous with the tumor indicates macrovascular invasion, not a routine intermediate-stage TACE setting. Selected locoregional approaches may be discussed by a specialist team, but the finding requires advanced-stage assessment and systemic-treatment consideration. [1]

   Reasoning steps for option D

   1. Why is the venous finding more concerning than an isolated filling defect?

      Arterially enhancing soft tissue continuous with HCC favors tumor in vein, which changes stage despite the small parenchymal tumor.

   2. How do the findings support or oppose this plan: Treat as intermediate-stage disease with routine TACE?

      Enhancing intravascular tissue continuous with the tumor indicates macrovascular invasion, not a routine intermediate-stage TACE setting. Selected locoregional approaches may be discussed by a specialist team, but the finding requires advanced-stage assessment and systemic-treatment consideration. [1]

Takeaway: Likely tumor in vein changes stage and generally excludes standard transplant eligibility; systemic treatment is considered with adequate reserve.

Case sources: [1]

1. A. Start systemic HCC therapy for presumed vascular invasion (Why this does not fit)

   The nonenhancing, nonexpansile, separate clot does not establish tumor in vein requiring systemic therapy. [1]

   Reasoning steps for option A

   1. Which supplied observations favor bland rather than malignant thrombosis?

      No internal arterial enhancement, expansion or tumor continuity is seen. This does not establish macrovascular tumor invasion.

   2. How do the findings support or oppose this plan: Start systemic HCC therapy for presumed vascular invasion?

      The nonenhancing, nonexpansile, separate clot does not establish tumor in vein requiring systemic therapy. [1]

2. B. Biopsy the portal-vein defect before proceeding with transplant assessment (Why this does not fit)

   The adequately assessed nonenhancing, nonexpansile defect favors bland clot. Invasive sampling is not the default first step for that pattern, and transplant assessment need not automatically stop while the clot is evaluated. [1]

   Reasoning steps for option B

   1. Which supplied observations favor bland rather than malignant thrombosis?

      No internal arterial enhancement, expansion or tumor continuity is seen. This does not establish macrovascular tumor invasion.

   2. How do the findings support or oppose this plan: Biopsy the portal-vein defect before proceeding with transplant assessment?

      The adequately assessed nonenhancing, nonexpansile defect favors bland clot. Invasive sampling is not the default first step for that pattern, and transplant assessment need not automatically stop while the clot is evaluated. [1]

3. C. Delay transplant evaluation until portal flow is restored (Why this does not fit)

   A likely bland clot does not automatically terminate transplant evaluation. [1]

   Reasoning steps for option C

   1. Which supplied observations favor bland rather than malignant thrombosis?

      No internal arterial enhancement, expansion or tumor continuity is seen. This does not establish macrovascular tumor invasion.

   2. How do the findings support or oppose this plan: Delay transplant evaluation until portal flow is restored?

      A likely bland clot does not automatically terminate transplant evaluation. [1]

4. D. Continue transplant evaluation while assessing portal-vein thrombosis (Best answer)

   Imaging favors bland thrombosis; assess its extent and management in parallel with transplant candidacy. [1]

   Reasoning steps for option D

   1. Which supplied observations favor bland rather than malignant thrombosis?

      No internal arterial enhancement, expansion or tumor continuity is seen. This does not establish macrovascular tumor invasion.

   2. How do the findings support or oppose this plan: Continue transplant evaluation while assessing portal-vein thrombosis?

      Imaging favors bland thrombosis; assess its extent and management in parallel with transplant candidacy. [1]

Takeaway: Imaging favors bland thrombosis; assess its extent and management in parallel with transplant candidacy.

Case sources: [1]

1. A. Selective transarterial tumor treatment (Best answer)

   Multifocal liver-confined disease without invasion or spread is being considered together with preserved hepatic reserve and portal flow. A selective transarterial approach is appropriate to discuss after procedural planning when curative resection, ablation and transplantation are unavailable; systemic therapy is not selected solely because there is more than one tumor. [1]

   Reasoning steps for option A

   1. How do tumor extent and hepatic reserve affect this choice?

      The disease is multifocal but liver-confined without invasion. Preserved reserve and portal flow support discussion of selective transarterial therapy when curative options are unavailable.

   2. How do the findings support or oppose this plan: Selective transarterial tumor treatment?

      Multifocal liver-confined disease without invasion or spread is being considered together with preserved hepatic reserve and portal flow. A selective transarterial approach is appropriate to discuss after procedural planning when curative resection, ablation and transplantation are unavailable; systemic therapy is not selected solely because there is more than one tumor. [1]

2. B. Resection of the largest liver mass (Why this does not fit)

   Removing one lesion leaves multifocal bilobar tumor untreated. [1]

   Reasoning steps for option B

   1. How do tumor extent and hepatic reserve affect this choice?

      The disease is multifocal but liver-confined without invasion. Preserved reserve and portal flow support discussion of selective transarterial therapy when curative options are unavailable.

   2. How do the findings support or oppose this plan: Resection of the largest liver mass?

      Removing one lesion leaves multifocal bilobar tumor untreated. [1]

3. C. First-line systemic anticancer therapy (Why this does not fit)

   Systemic therapy is appropriate if liver-directed control is unsuitable or fails, but selective arterial therapy is currently feasible. [1]

   Reasoning steps for option C

   1. How do tumor extent and hepatic reserve affect this choice?

      The disease is multifocal but liver-confined without invasion. Preserved reserve and portal flow support discussion of selective transarterial therapy when curative options are unavailable.

   2. How do the findings support or oppose this plan: First-line systemic anticancer therapy?

      Systemic therapy is appropriate if liver-directed control is unsuitable or fails, but selective arterial therapy is currently feasible. [1]

4. D. Listing for liver transplantation (Why this does not fit)

   Four lesions fall outside standard Milan criteria, although selected downstaging assessment may be considered separately. [1]

   Reasoning steps for option D

   1. How do tumor extent and hepatic reserve affect this choice?

      The disease is multifocal but liver-confined without invasion. Preserved reserve and portal flow support discussion of selective transarterial therapy when curative options are unavailable.

   2. How do the findings support or oppose this plan: Listing for liver transplantation?

      Four lesions fall outside standard Milan criteria, although selected downstaging assessment may be considered separately. [1]

Takeaway: Liver-limited multifocal disease with reserve and actual selective arterial access supports transarterial treatment discussion.

Case sources: [1]

1. A. Major hepatic resection after detailed anatomical assessment (Why this does not fit)

   Severe synthetic impairment and decompensation make major resection unsafe. [1]

   Reasoning steps for option A

   1. Does confinement to the liver establish treatment tolerance?

      No. Refractory ascites, encephalopathy, high bilirubin and INR, and low albumin indicate severely impaired reserve without a transplant pathway.

   2. How do the findings support or oppose this plan: Major hepatic resection after detailed anatomical assessment?

      Severe synthetic impairment and decompensation make major resection unsafe. [1]

2. B. Symptom-focused care and treatment of hepatic decompensation (Best answer)

   Severe hepatic failure without transplant access limits benefit and tolerability of standard HCC-directed treatment despite liver-limited disease. [1]

   Reasoning steps for option B

   1. Does confinement to the liver establish treatment tolerance?

      No. Refractory ascites, encephalopathy, high bilirubin and INR, and low albumin indicate severely impaired reserve without a transplant pathway.

   2. How do the findings support or oppose this plan: Symptom-focused care and treatment of hepatic decompensation?

      Severe hepatic failure without transplant access limits benefit and tolerability of standard HCC-directed treatment despite liver-limited disease. [1]

3. C. Bilobar chemoembolization for control of multifocal liver disease (Why this does not fit)

   Embolization can further injure an already failing liver. [1]

   Reasoning steps for option C

   1. Does confinement to the liver establish treatment tolerance?

      No. Refractory ascites, encephalopathy, high bilirubin and INR, and low albumin indicate severely impaired reserve without a transplant pathway.

   2. How do the findings support or oppose this plan: Bilobar chemoembolization for control of multifocal liver disease?

      Embolization can further injure an already failing liver. [1]

4. D. Combination immune checkpoint therapy for liver-limited disease (Why this does not fit)

   First-line immunotherapy evidence comes largely from much better compensated patients and does not establish benefit here. [1]

   Reasoning steps for option D

   1. Does confinement to the liver establish treatment tolerance?

      No. Refractory ascites, encephalopathy, high bilirubin and INR, and low albumin indicate severely impaired reserve without a transplant pathway.

   2. How do the findings support or oppose this plan: Combination immune checkpoint therapy for liver-limited disease?

      First-line immunotherapy evidence comes largely from much better compensated patients and does not establish benefit here. [1]

Takeaway: Severe hepatic failure without transplant access limits benefit and tolerability of standard HCC-directed treatment despite liver-limited disease.

Case sources: [1]

1. A. Repeat selective TACE for the remaining viable tumors (Why this does not fit)

   Progressive viable tumor after adequate delivery argues against automatic repetition of the same strategy. [1]

   Reasoning steps for option A

   1. What does persistent and increasing nodular enhancement after two adequate sessions imply?

      Together with new nodules, it supports persistent viable progressive disease rather than successful local control.

   2. How do the findings support or oppose this plan: Repeat selective TACE for the remaining viable tumors?

      Progressive viable tumor after adequate delivery argues against automatic repetition of the same strategy. [1]

2. B. Continue interval imaging without further cancer-directed treatment (Why this does not fit)

   Progression confined to the liver still warrants treatment reassessment. [1]

   Reasoning steps for option B

   1. What does persistent and increasing nodular enhancement after two adequate sessions imply?

      Together with new nodules, it supports persistent viable progressive disease rather than successful local control.

   2. How do the findings support or oppose this plan: Continue interval imaging without further cancer-directed treatment?

      Progression confined to the liver still warrants treatment reassessment. [1]

3. C. Change the treatment discussion to systemic therapy (Best answer)

   Increasing viable enhancement and new nodules indicate failure of locoregional control, while reserve remains adequate to consider systemic therapy. [1]

   Reasoning steps for option C

   1. What does persistent and increasing nodular enhancement after two adequate sessions imply?

      Together with new nodules, it supports persistent viable progressive disease rather than successful local control.

   2. How do the findings support or oppose this plan: Change the treatment discussion to systemic therapy?

      Increasing viable enhancement and new nodules indicate failure of locoregional control, while reserve remains adequate to consider systemic therapy. [1]

4. D. Proceed to transplant listing without further tumor reduction (Why this does not fit)

   An immediate listing plan is unsupported: this patient has no current curative pathway and has viable progression despite adequate treatment. Transplant eligibility cannot be inferred simply because the disease remains liver-confined. [1]

   Reasoning steps for option D

   1. What does persistent and increasing nodular enhancement after two adequate sessions imply?

      Together with new nodules, it supports persistent viable progressive disease rather than successful local control.

   2. How do the findings support or oppose this plan: Proceed to transplant listing without further tumor reduction?

      An immediate listing plan is unsupported: this patient has no current curative pathway and has viable progression despite adequate treatment. Transplant eligibility cannot be inferred simply because the disease remains liver-confined. [1]

Takeaway: Increasing viable enhancement and new nodules indicate failure of locoregional control, while reserve remains adequate to consider systemic therapy.

Case sources: [1]

1. A. Atezolizumab plus bevacizumab (Why this does not fit)

   Bevacizumab inhibits VEGF signaling, which is relevant to gastrointestinal bleeding risk. Successful acute variceal treatment does not erase the relevance of a recent hemorrhage to regimen selection. [1]

   Reasoning steps for option A

   1. Which therapeutic vascular pathway is relevant to the recent hemorrhage?

      VEGF-pathway inhibition is associated with bleeding concerns; treated varices do not erase the importance of a recent event.

   2. How do the findings support or oppose this plan: Atezolizumab plus bevacizumab?

      Bevacizumab inhibits VEGF signaling, which is relevant to gastrointestinal bleeding risk. Successful acute variceal treatment does not erase the relevance of a recent hemorrhage to regimen selection. [1]

2. B. Nivolumab plus ipilimumab (Best answer)

   The recent variceal bleed raises concern about VEGF-pathway inhibition. Nivolumab targets PD-1 and ipilimumab targets CTLA-4, providing an approved first-line approach without that vascular target when immune therapy is otherwise appropriate. [1,2]

   Reasoning steps for option B

   1. Which therapeutic vascular pathway is relevant to the recent hemorrhage?

      VEGF-pathway inhibition is associated with bleeding concerns; treated varices do not erase the importance of a recent event.

   2. How do the findings support or oppose this plan: Nivolumab plus ipilimumab?

      The recent variceal bleed raises concern about VEGF-pathway inhibition. Nivolumab targets PD-1 and ipilimumab targets CTLA-4, providing an approved first-line approach without that vascular target when immune therapy is otherwise appropriate. [1,2]

3. C. Sorafenib monotherapy (Why this does not fit)

   Sorafenib inhibits VEGF-receptor signaling among its kinase targets. Although it is an HCC treatment option, it does not avoid the vascular pathway implicated in the bleeding-risk concern. [1]

   Reasoning steps for option C

   1. Which therapeutic vascular pathway is relevant to the recent hemorrhage?

      VEGF-pathway inhibition is associated with bleeding concerns; treated varices do not erase the importance of a recent event.

   2. How do the findings support or oppose this plan: Sorafenib monotherapy?

      Sorafenib inhibits VEGF-receptor signaling among its kinase targets. Although it is an HCC treatment option, it does not avoid the vascular pathway implicated in the bleeding-risk concern. [1]

4. D. Lenvatinib monotherapy (Why this does not fit)

   Lenvatinib inhibits VEGF-receptor signaling among its kinase targets. It is not a nonangiogenic substitute merely because it is an oral drug rather than bevacizumab. [1]

   Reasoning steps for option D

   1. Which therapeutic vascular pathway is relevant to the recent hemorrhage?

      VEGF-pathway inhibition is associated with bleeding concerns; treated varices do not erase the importance of a recent event.

   2. How do the findings support or oppose this plan: Lenvatinib monotherapy?

      Lenvatinib inhibits VEGF-receptor signaling among its kinase targets. It is not a nonangiogenic substitute merely because it is an oral drug rather than bevacizumab. [1]

Takeaway: Infer the relevant treatment risk from the clinical complication, then compare drug targets rather than brand or delivery route.

Case sources: [1] [2]

1. A. Start nivolumab maintenance on the planned schedule (Why this does not fit)

   Nivolumab alone is the usual treatment after the finite four-dose induction. However, the new synthetic dysfunction, ascites and altered mentation require prompt assessment rather than automatic infusion because tumors have become smaller. [1,2,6,10]

   Reasoning steps for option A

   1. Do smaller tumor measurements establish current treatment tolerance?

      No. Newly abnormal synthetic function, ascites and disorientation indicate decompensation requiring prompt evaluation. The usual switch after four combination doses is to nivolumab alone, but that schedule must not override the new deterioration.

   2. How do the findings support or oppose this plan: Start nivolumab maintenance on the planned schedule?

      Nivolumab alone is the usual treatment after the finite four-dose induction. However, the new synthetic dysfunction, ascites and altered mentation require prompt assessment rather than automatic infusion because tumors have become smaller. [1,2,6,10]

2. B. Give another combination dose before maintenance begins (Why this does not fit)

   The prescribed combination induction is limited to four doses. An additional dual-checkpoint dose neither addresses the new liver deterioration nor follows the maintenance schedule. [2]

   Reasoning steps for option B

   1. Do smaller tumor measurements establish current treatment tolerance?

      No. Newly abnormal synthetic function, ascites and disorientation indicate decompensation requiring prompt evaluation. The usual switch after four combination doses is to nivolumab alone, but that schedule must not override the new deterioration.

   2. How do the findings support or oppose this plan: Give another combination dose before maintenance begins?

      The prescribed combination induction is limited to four doses. An additional dual-checkpoint dose neither addresses the new liver deterioration nor follows the maintenance schedule. [2]

3. C. Defer maintenance and evaluate hepatic decompensation (Best answer)

   The target-lesion sum has decreased by 35%, but the new laboratory and clinical findings indicate severe hepatic decompensation. Defer the routine infusion and urgently assess causes, including treatment toxicity and other precipitants, with liver-directed supportive care and multidisciplinary reassessment; improved tumor measurements do not establish current treatment tolerance. [1,2,6,10] Whether this medication can be resumed depends on the identified cause and severity; resumption is not assumed. [10]

   Reasoning steps for option C

   1. Do smaller tumor measurements establish current treatment tolerance?

      No. Newly abnormal synthetic function, ascites and disorientation indicate decompensation requiring prompt evaluation. The usual switch after four combination doses is to nivolumab alone, but that schedule must not override the new deterioration.

   2. How do the findings support or oppose this plan: Defer maintenance and evaluate hepatic decompensation?

      The target-lesion sum has decreased by 35%, but the new laboratory and clinical findings indicate severe hepatic decompensation. Defer the routine infusion and urgently assess causes, including treatment toxicity and other precipitants, with liver-directed supportive care and multidisciplinary reassessment; improved tumor measurements do not establish current treatment tolerance. [1,2,6,10] Whether this medication can be resumed depends on the identified cause and severity; resumption is not assumed. [10]

4. D. Switch to sorafenib despite the radiographic response (Why this does not fit)

   There is no supplied evidence of tumor progression requiring a different anticancer drug. Substituting a kinase inhibitor does not resolve the new severe liver dysfunction or establish that systemic treatment is tolerable. [1,6]

   Reasoning steps for option D

   1. Do smaller tumor measurements establish current treatment tolerance?

      No. Newly abnormal synthetic function, ascites and disorientation indicate decompensation requiring prompt evaluation. The usual switch after four combination doses is to nivolumab alone, but that schedule must not override the new deterioration.

   2. How do the findings support or oppose this plan: Switch to sorafenib despite the radiographic response?

      There is no supplied evidence of tumor progression requiring a different anticancer drug. Substituting a kinase inhibitor does not resolve the new severe liver dysfunction or establish that systemic treatment is tolerable. [1,6]

Takeaway: Finite induction normally leads to nivolumab maintenance, but new hepatic decompensation changes whether treatment should proceed.

Case sources: [1] [2] [6] [10]

1. A. Definite HCC; proceed to staging and tumor treatment (Why this does not fit)

   Transitional-phase hypointensity is not qualifying washout for LR-5 with gadoxetate. [1] [4]

   Reasoning steps for option A

   1. Does transitional darkness count as portal venous washout with gadoxetate?

      No. Background uptake can cause transitional hypointensity; this finding cannot provide the missing definite-HCC major feature.

   2. How do the findings support or oppose this plan: Definite HCC; proceed to staging and tumor treatment?

      Transitional-phase hypointensity is not qualifying washout for LR-5 with gadoxetate. [1] [4]

2. B. Benign observation; continue six-month ultrasound and AFP (Why this does not fit)

   Lack of portal washout does not prove an arterialized lesion benign. [1] [4]

   Reasoning steps for option B

   1. Does transitional darkness count as portal venous washout with gadoxetate?

      No. Background uptake can cause transitional hypointensity; this finding cannot provide the missing definite-HCC major feature.

   2. How do the findings support or oppose this plan: Benign observation; continue six-month ultrasound and AFP?

      Lack of portal washout does not prove an arterialized lesion benign. [1] [4]

3. C. Malignant-nonspecific observation; obtain biopsy for histologic classification (Why this does not fit)

   LR-M concerns malignant patterns not specific for HCC, such as targetoid morphology. The supplied finding is transitional hypointensity, which is not portal venous washout and does not by itself establish LR-M. [1,4,9]

   Reasoning steps for option C

   1. Does transitional darkness count as portal venous washout with gadoxetate?

      No. Background uptake can cause transitional hypointensity; this finding cannot provide the missing definite-HCC major feature.

   2. How do the findings support or oppose this plan: Malignant-nonspecific observation; obtain biopsy for histologic classification?

      LR-M concerns malignant patterns not specific for HCC, such as targetoid morphology. The supplied finding is transitional hypointensity, which is not portal venous washout and does not by itself establish LR-M. [1,4,9]

4. D. Indeterminate observation; repeat short-interval contrast imaging (Best answer)

   Transitional hypointensity may be an ancillary malignancy feature but does not by itself establish LR-5; multidisciplinary review and interval multiphasic imaging are appropriate. [1] [4]

   Reasoning steps for option D

   1. Does transitional darkness count as portal venous washout with gadoxetate?

      No. Background uptake can cause transitional hypointensity; this finding cannot provide the missing definite-HCC major feature.

   2. How do the findings support or oppose this plan: Indeterminate observation; repeat short-interval contrast imaging?

      Transitional hypointensity may be an ancillary malignancy feature but does not by itself establish LR-5; multidisciplinary review and interval multiphasic imaging are appropriate. [1] [4]

Takeaway: Transitional hypointensity may be an ancillary malignancy feature but does not by itself establish LR-5; multidisciplinary review and interval multiphasic imaging are appropriate.

Case sources: [1] [4] [9]